Telaglenastat

Generic Name: Telaglenastat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₄F_₃N_₇O_₃S

CAS Number: 1439399-58-2

Unique Ingredient Identifier: U6CL98GLP4

Background: Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Metastatic Malignant Neoplasm in the Brain
Stage IV Lung Cancer AJCC v8
Leptomeningeal Neoplasm
Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma

Interventions: Drug: Sapanisertib
Drug: Telaglenastat Hydrochloride

First Posted Date: 2020-01-31

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 85

Registration Number: NCT04250545

Locations: 🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States

and more 4 locations

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Phase 2

Active, not recruiting

Conditions: NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor
Metastatic Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Pharmacodynamic Study
Procedure: Positron Emission Tomography
Drug: Telaglenastat Hydrochloride

First Posted Date: 2019-03-13

Last Posted Date: 2024-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 108

Registration Number: NCT03872427

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 28 locations

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Small Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Elastography
Drug: Osimertinib
Procedure: Positron Emission Tomography
Drug: Telaglenastat Hydrochloride
Procedure: X-Ray Imaging

First Posted Date: 2019-02-06

Last Posted Date: 2025-01-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT03831932

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 8 locations

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Refractory Multiple Myeloma
Recurrent Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Telaglenastat Hydrochloride

First Posted Date: 2019-01-10

Last Posted Date: 2024-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT03798678

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 2 locations

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Phase 1

Active, not recruiting

Conditions: Astrocytoma, IDH-Mutant, Grade 2
Astrocytoma, IDH-Mutant, Grade 3

Interventions: Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Telaglenastat Hydrochloride
Drug: Temozolomide

First Posted Date: 2018-05-18

Last Posted Date: 2024-11-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03528642

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 22 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy